Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention
Authors:
Open Access
- 2 June 2026
- journal article
- research article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0196625
Abstract
Griffithsin (GRFT) is an antiviral lectin that blocks human immunodeficiency virus (HIV) entry. When combined with carrageenan (CG), GRFT has strong activity against herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV). We conducted a preclinical evaluation of a high-dose vaginal fast-dissolving insert (FDI) containing 3 mg GRFT—equivalent to 3× the clinical dose—and compared it with a 1 mg formulation. Studies included FDI disintegration (macaques, rabbits); GRFT pharmacokinetics, pharmacodynamics, and inflammatory response (macaques); toxicity (rats); and immunogenicity (macaques, rats). Disintegration times varied between species, emphasizing the importance of evaluating this parameter in humans. In macaques, cervico-vaginal lavage (CVL) GRFT concentrations exceeded levels associated with in vivo efficacy 12 h after administration of the 3 mg GRFT/CG FDI. Potent anti-HIV1 BaL activity was detected in CVLs collected 24 h following the 3 mg dose and 12 h after the 1 mg dose. CVLs inhibited HSV-2 at 4 h and HPV at 12 h after both GRFT doses. GRFT/CG FDIs caused no inflammatory response and did not alter vaginal pH. In rats, repeated daily dosing at up to 10× the clinical dose revealed no safety concerns. Although anti-drug antibodies (ADAs) developed in macaques and rats, systemic GRFT was undetectable, suggesting that ADAs are unlikely to alter pharmacokinetics. Overall, the CVL GRFT concentrations and anti-HIV activity following administration of 3 mg GRFT/CG FDIs suggest a longer protection window—at least 12 h—against HIV-1 compared with the 1 mg FDI, and both formulations demonstrate activity against HSV-2 and HPV. These findings support continued GRFT/CG FDI development. IMPORTANCE: There is an undeniable need to develop multipurpose prevention products that simultaneously protect against human immunodeficiency virus (HIV) and other sexually transmitted pathogens. To that end, we conducted a preclinical evaluation of a carrageenan-based fast-dissolving vaginal insert containing 3 mg of anti-viral lectin Griffithsin—equivalent to 3× clinical dose—and compared it with a 1 mg insert. Both formulations were safe and demonstrated potent anti-HIV, herpes simplex virus type 2 (HSV-2), and human papillomavirus (HPV) activity. Our data suggest that a 3× clinical dose Griffithsin formulation may afford an extended window of protection against HIV compared to the 1× dose formulation. These data support further development and clinical testing of high-dose Griffithsin carrageenan fast-dissolving vaginal insert.Keywords
Funding Information
- United States Agency for International Development (Cooperative Agreement #7200AA22CA00002)
This publication has 40 references indexed in Scilit:
- Human papilloma virus vaccination in the resource-limited settings of sub-Saharan Africa: Challenges and recommendationsVaccine: X, 2024
- Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in DevelopmentAIDS and Behavior, 2023
- Variation in Human Papillomavirus Vaccination Effectiveness in the US by Age at VaccinationJAMA Network Open, 2022
- Comparing endocervical mucus proteome of humans and rhesus macaquesProteomics – Clinical Applications, 2021
- Development of a Vaginal Fast-Dissolving Insert Combining Griffithsin and Carrageenan for Potential Use Against Sexually Transmitted InfectionsJournal of Pharmaceutical Sciences, 2018
- Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivoNature Communications, 2018
- Interest in multipurpose prevention technologies to prevent HIV/STIs and unintended pregnancy among young women in the United StatesContraception, 2018
- Vaginal drug distribution modelingAdvanced Drug Delivery Reviews, 2015
- Multipurpose prevention technologies: the future of HIV and STI protectionTrends in Microbiology, 2015
- Structure‐based redesign of proteins for minimal T‐cell epitope contentJournal of Computational Chemistry, 2013